Check Claims Before You Publish

 Quick Explanation Copied

 Long Explanation

Discovery Impact: DC-SIGN and the Glyco-Code

Van Kooyk's scientific strength rests on two back-to-back 2000 Cell papers: identification of DC-SIGN as a dendritic cell–specific ICAM-3 receptor supporting primary immune responses (1,716 citations) and as an HIV-1 binding protein enhancing trans-infection of T cells (2,455 citations) DC-SIGN ICAM-3 receptor discovery DC-SIGN HIV trans-infection. She then translated the discovery mechanistically: mycobacteria targeting DC-SIGN to suppress dendritic cell function Mycobacteria exploit DC-SIGN, antigen internalization for T-cell presentation DC-SIGN antigen internalization, and Langerin acting as a natural barrier to HIV-1 transmission Langerin HIV barrier. Her field-defining reviews on pathogen escape DC-SIGN pathogen escape review and protein-glycan immune control Glycan-immune control framework establish her as a conceptual leader, not merely a discoverer.

The 2000–2002 citation spike (6,190 + 4,161 + 2,091 citations in three years) reflects the DC-SIGN discovery's immediate field-wide absorption.

Recent Scientific Quality from Extracted Papers

Extracted full-text analyses of her papers show consistently high quality with a small-sample caveat in the histology work Lymph node DC-SIGN/L-SIGN histology, n=6. Her 2021 Nature Communications paper shows sustained translational depth: PDAC α2,3-sialylation driving Siglec-7/9–mediated TAM differentiation, validated across multiple public datasets and CRISPR/Siglec-blockade perturbations PDAC sialylation-Siglec TAM axis. A caveat: the 2016 eLife myelin/BBB work scores lower (7/10 quality, 6/10 reproducibility), relying on in vitro hCMEC/D3 and transgenic murine models without in vivo confirmation Brain endothelium myelin presentation.

Critical Caveats

• Metrics discrepancy: a secondary citation record reports h-index 8 / 328 citations / 18 papers, which conflicts sharply with OpenAlex (h-index 101, 467 works, 38,972 citations); the OpenAlex record, matched to ORCID 0000-0001-5997-3665 and containing her known landmark papers, is almost certainly the correct one — the secondary record is likely a fragmented author disambiguation error.
• Blindspot pattern: several papers rely on in vitro or ex vivo human models with limited in vivo validation (lymph node histology n=6; BBB transwell assays; lactoferrin microbicide studies without mucosal efficacy data Lactoferrin blocks DC-SIGN-gp120).
• Strength of blood DC work: the Blood paper identifying rare DC-SIGN+ blood DCs (0.01–0.04% of PBMCs) as HIV transmitters is methodologically careful, with DC-SIGN blockade controls DC-SIGN+ blood DC subset.

 BGPT Author Review

Scientific Quality

Van Kooyk co-discovered DC-SIGN, a genuinely field-creating contribution published in Cell with thousands of citations, and maintained 40 years of high-impact output spanning HIV transmission, tuberculosis, probiotics, cancer glycobiology, and the BBB. The glyco-code/Siglec axis work shows continuing mechanistic depth. Deductions: frequent reliance on in vitro/ex vivo human models with limited in vivo validation, small sample sizes in histology work, and one paper (myelin/BBB) with modest reproducibility scores.

Communication Quality

Her field reviews (Nature Reviews Immunology, Nature Immunology) are highly cited, indicating exceptional ability to frame and communicate new concepts to the field. Extracted papers are well-structured with clear tables and quantitative reporting. Communication deductions arise because some primary papers leave functional claims as inference rather than direct demonstration, requiring careful reader interpretation.

Author Novelty

The DC-SIGN discovery papers and subsequent glyco-immunology framework (protein-glycan immune control, tumor glyco-code) opened new research territories. The Siglec-sialic acid TAM work extended a known axis but with genuinely new tumor-specific evidence. Novelty scores are capped by her later translational/extension work being incremental relative to her own foundational contributions.

Scientific Rigor

Strong rigor in antibody validation, blocking controls, CRISPR perturbations, and multi-dataset validation (PDAC paper scored 9/10). Rigor is weakened by small samples (n=6 lymph node patients), absent data repositories in earlier work, incomplete donor reporting in some virology studies, and an in vitro-centric BBB study with reproducibility rated 6/10.